FDA Announces Expedited IND Pilot to Accelerate Clinical Trial Timelines

The U.S. Food and Drug Administration (FDA) has announced the final design of the Expedited Investigational New Drug (IND) Pilot, a program aimed at accelerating the timeline from drug identification to the initiation of first-in-human clinical trials. The pilot is a key component of the Trump Administration's healthcare modernization efforts and is part of the U.S. Department of Health and Human Services' Operation TrialBlazer.

Under the current system, first-in-human clinical trials in the United States may take up to two years to complete. The FDA notes that similar trials are completed much faster in China and Australia, and the pilot seeks to address this disparity to maintain American leadership in medical innovation. The program is designed to partner drug companies with qualified research institutions (QRIs) that possess scientific expertise to support the efficient development of IND applications.

The pilot will utilize a rolling review process during the pre-IND phase. This allows the FDA to review and accept individual components of an IND application as they are submitted, rather than waiting for all components to be complete before beginning review. The goal is to identify and resolve issues in real time sooner, reducing the risk of the FDA placing a clinical trial protocol on hold during the standard 30-day IND review period.

Applications to participate in the pilot will be accepted by the FDA until October 30, 2026. Drug sponsors and prospective QRIs must apply as a pair. The FDA expects that 8 to 10 Sponsor-QRI pairs will be selected for the initial pilot cohort. The agency retains full regulatory authority throughout the program, including the responsibility for determining whether a clinical investigation may proceed or if a clinical hold should be imposed.

The pilot is intended to generate evidence to inform potential future policy initiatives, such as a formal accreditation model that would recognize QRIs demonstrating strong scientific and regulatory judgment. This would aim to create a sustainable, high-quality network of institutions to support drug development. The FDA has incorporated public feedback received on the proposed pilot into the final design.